The 64 slides were randomized, assigned unique identification numbers, and reviewed by a blinded mycobacteriologist.
Mice were randomized and assigned to treatment groups consisting of everolimus (gavage, 10 mg/kg, 3×/week) or U0126 (i.p. 20 mg/kg/d) for 4 weeks.
Male (Mecp2 Null/Y), female (Mecp2 Null/+), and littermate wild-type (WT) controls were randomized and assigned to a treatment cohort.
The patients will be randomized and assigned to the standard group and the methylene blue-assisted group by a centralized dynamic method using the following factors: lymphadenectomy (D1+/D2), type of gastrectomy (subtotal/total), and surgical experience (less than 15 years/15 years-).
A final pool of 45 qualified individuals were randomized, with 22 assigned to DTG and 23 assigned to CG. Demographic, anthropometric, cognitive, medication, and comorbidity characteristics of the participants at baseline are shown in Table 1.
In brief, participants were randomized to assigned treatment groups using a permuted block randomization scheme, with block size stratified by study site.
As Figure 3 shows, of the 472 participants who enrolled in the initial weight loss program, 285 (60%) achieved weight loss and attendance targets and were randomized, with 142 assigned to TAT and 143 to SS.
In total 125 subjects were recruited in the study and all were randomized; 67 were assigned to CIN 75 mg and 58 to SV 800 mg.
The remaining 41 were randomized, with 21 assigned to the experimental group and 20 to the control group.
Volunteers were randomized to 6 groups assigned to vaccine formulations of decreasing amounts of viral particles.
